{"id":"W4415900074","doi":"10.1016/s2352-3026(25)00264-9","title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Clinical trial; Phases of clinical research; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001223186,0.0007020744,0.004523632,0.0003091112,0.0002574691,0.000132444,0.0007828618,0.000256014,0.0005724908],"category_scores_gemma":[0.0006190625,0.0003943091,0.0001919143,0.0004723406,0.0002543327,0.0002406614,0.0004513341,0.0009090685,0.0001182042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003358798,"about_ca_system_score_gemma":0.0005244573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008733755,"about_ca_topic_score_gemma":0.004508649,"domain_scores_codex":[0.9949071,0.001629532,0.001157771,0.0009955785,0.0003888572,0.0009211074],"domain_scores_gemma":[0.9961169,0.001914454,0.0004267751,0.001196736,0.0001647572,0.000180404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8085065,0.06688721,0.05176089,0.0006606414,0.008194263,0.01279076,0.01342275,0.00009032237,0.005394163,0.004897799,0.01547926,0.01191536],"study_design_scores_gemma":[0.9645314,0.004085801,0.009714996,0.0009243861,0.002216961,0.0005187921,0.001911847,0.002926311,0.008360059,0.0004290421,0.003748758,0.000631625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9681416,0.0009835789,0.0001428874,0.0128,0.0006295712,0.01079567,0.00003777918,0.0001108388,0.006358091],"genre_scores_gemma":[0.9917485,0.0004939807,0.0002402838,0.003048705,0.0001849308,0.0028897,0.00006371364,0.00005881161,0.001271395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1560248,"threshold_uncertainty_score":0.9998509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05743628741329941,"score_gpt":0.4161781471176606,"score_spread":0.3587418597043612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}